Kornimate/medical-research-clean huggingface dataset:
efficacy of transdermal fentanyl patches in relief of acute postoperative pain after mastectomy

Conditions: Breast Cancer Female

Summary: to determine the safety, efficacy and tolerability of transdermal fentanyl in patients undergoing mastectomy, as well as the postoperative consumption of analgesic.


Eligibility criteria:
inclusion criteria: * asa i - ii patients * aged 30-60 years * body weight ranged between 65-10kg exclusion criteria: * patients with history of allergy to morphine * chronic intake of analgesics or non-steroidal anti-inflammatory drug 24 h prior to surgery, * there was a history of a psychiatric disorder patients weight was less then 50kg. * impaired kidney function.
a study to assess the pk and pharmacodynamics of ipx203 in patients with advanced parkinson's disease

Conditions: Parkinson's Disease

Summary: this is a randomized, open-label, rater-blinded, multicenter, 3-treatment, 3 period, single-dose crossover study. approximately 51 qualified immediate-release (ir) cd-ld-experienced advanced parkinson's disease patients will be randomized to 1 of 3 dosing sequences. objectives: * assess the pharmacodynamics and pharmacokinetics (pk) of ipx203 (carbidopa and levodopa) in subjects with advanced parkinson's disease. * characterize the safety of ipx203 in subjects with advanced parkinson's disease.

ipx203 contains two different drugs called levodopa and carbidopa in one capsule. * levodopa turns into a material called 'dopamine' in your brain. the dopamine helps to improve the symptoms of your parkinson's disease. * carbidopa belongs to a group of medicines called 'aromatic amino acid decarboxylase inhibitors'. it helps levodopa work more effectively by slowing the speed at which levodopa is broken down in your body.

Eligibility criteria:
inclusion criteria: male or female subjects diagnosed with idiopathic pd with motor complications, who are currently being treated chronically with stable regimens of cd-ld. requiring at least 400 mg but not more than 1600 mg ld per day during the waking hours; and at least 100 mg but not more than 250 mg ld from ir cd-ld for the first morning dose. dosing frequency of ir cd-ld of at least 4 times daily excluding nighttime dosing. have an average of at least 2 hours per day "off" time during the waking hours and at least 1 hour "off" time per day, based on the pd diary collected for 3 consecutive days prior to visit 1. exclusion criteria: have used first morning dose of controlled-release (cr) cd-ld or rytary for at least 4 weeks prior to visit 1. female subjects who are currently breastfeeding or lactating. had prior functional neurosurgical treatment for pd (ablation or deep brain stimulation) or if such procedure(s) are planned or anticipated during the study period. allergic to study drugs history of medical conditions or of a prior surgical procedure that would interfere with ld absorption, such as gastrectomy or small-bowel resection. history of peptic ulcer disease or upper gastrointestinal hemorrhage. history of narrow angle glaucoma. history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias; neuroleptic malignant syndrome; or nontraumatic rhabdomyolysis. history of psychosis. employees or family members of the investigator, study site, or sponsor. subjects who, in the opinion of the clinical investigator, should not participate in the study. based on clinical assessment, subject does not adequately comprehend the terminology needed to complete the pd diary.
pre-operative epirubicin, cisplatin, and capecitabine in patients with newly diagnosed localised oesophageal adenocarcinoma

Conditions: Adenocarcinoma of Oesophagus

Summary: to investigate the efficacy and safety of epirubicin, cisplatin and capecitabine as neoadjuvant therapy prior to radical resection in patients with newly diagnosed operable oesophageal adenocarcinoma.


Eligibility criteria:
inclusion criteria: * age \> 18 years. * histologically verified adenocarcinoma of the thoracic oesophagus or type 1, 2 and 3 tumours of the oesophagogastric junction (type 1 refers to lower oesophageal, type 2 refers to cardial and type 3 refers to subcardinal cancers). * ajcc stage ii-iii (t2-3 n0-1 m0) (28), as assessed by spiral or multi-slice ct and endoscopic ultrasound, where primary surgery would be considered with curative intent. * no previous chemotherapy, radiotherapy or other investigational drug treatment for this indication. * who performance status 0,1 or 2. * adequate bone marrow function with platelets \> 100 x 109/l; wbc \> 3 x 109/l; neutrophils \> 1.5 x 109/l at the time of study entry. * serum bilirubin \< 35 mol/l. * serum creatinine \< 180 mol/l and measured creatinine clearance over 60ml/min. * no concurrent uncontrolled medical condition. * no previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix in the last 10 years. * life expectancy \> 3 months. * adequate contraceptive precautions if relevant. * informed written consent. exclusion criteria: * the presence of locally advanced or metastatic disease precluding curative surgical resection (t4 or stage iv or m1a-b) * total dysphagia (o'rourke's swallowing function scoring system 5) precluding swallowing of capecitabine even when crushed * medical or psychiatric conditions that compromise the patient's ability to give informed consent. * patients with disease in any of the following areas on the basis of ct scan and/or endoscopic ultrasound: * evidence of liver, lung or other distant metastases * para-aortic/coeliac lymphadenopathy \> 1cm diameter on ct, \> 6mm diameter on eus * invasion of airways, aorta, pericardium, or lung * new york heart association classification grade iii or iv. * uncontrolled angina pectoris. * pregnancy or breast feeding. * impaired renal function with measured creatinine clearance less than 60 ml/min. * known malabsorption syndromes. * patients with a known hypersensitivity to 5-fu or with a dihydropyrimidine dehydrogenase (dpd) deficiency.
effect of acute inflammatory mediators on functional limitations in patients with acute respiratory failure

Conditions: Acute Respiratory Failure

Summary: this is a randomized, controlled, pilot study of two separate cohorts of patients from the intensive care unit. cohort i will enroll 50 patients and randomize to receive one physical therapy session per day or receive usual icu care. cohort ii, will enroll an additional 50 patients and randomize to receive either two physical therapy sessions per day or usual care. outcome will be length of hospital stay measured in days. secondary outcomes will be mortality, ventilator days, icu days, and for cohort ii, grip strength, dynamometer strength assessments and the short physical performance battery (sppb). study subjects will have blood for cytokine analysis through their first week of study.


Eligibility criteria:
inclusion criteria: • mechanically ventilated via an endotracheal tube or mask exclusion criteria: * inability to walk without assistance prior to acute icu illness (use of a cane or walkers not exclusions) * cognitive impairment prior to acute icu illness (non-verbal) * preadmit immunocompromised (\>prednisone 20 mg/d for 2 wks) * acute stroke * body mass index (bmi) \>45 * neuromuscular disease that could impair weaning (myasthenia gravis, als, guillain-barre) * hip fracture, unstable cervical spine or pathological fracture * mech vent \>48 hours prior to transfer from an outside facility * current hospitalization or transferring hospital stay \>72 hours * cpr on admission, dnr on admission * hospitalization within 30 days prior to admission * cancer therapy within last 6 months * re-admission to icu within current hospitalization

Keywords: icu critical care intensive care critical illness acute respiratory failure mechanical ventilation physical therapy strength functional status short physical performance battery
ed-lead: emergency departments leading the transformation of alzheimer's and dementia care

Conditions: Alzheimer's Disease Related Dementia; Alzheimer Disease

Summary: the purpose of this study is to improve the care of persons living with dementia (plwd) and their informal care partners by addressing emergency and post-emergency care through different combinations of three plwd-care partner dyad focused interventions. the primary aims are to use coaching to help connect plwd and their care partners with community support and services to improve transitional care, quality of care, care satisfaction and reduce future ed visits and hospitalizations.


Eligibility criteria:
inclusion criteria: * patients age 66 and older * have two or more icd-10 visit diagnoses (one of which must be ambulatory) for alzheimer's disease or alzheimer's disease related dementias (ad/adrd) * care partners age 18 and older exclusion criteria: * patients who are under 66 years old

Keywords: dementia
tissue characterization with hyperspectral imaging (hsi)

Conditions: Tissue Perfusion; Tumor; Inflammation; Inflammatory Bowel Diseases

Summary: hyperspectral imaging (hsi) is a contact free method to analyse the from the tissue reflected light in the range of 500-1000nm. aim of the study is to identify special reflex patterns to identify special tissue

this hsi-camera provides hyperspectral images with a high spectral resolution (5 nm) in the visible and near infrared range (500-1000 nm). a rgb image and 4 false color images that represent physiologic parameters are intraoperatively provided by an analysis software. but after the procedure all spectral datasets could be investigated. to analyse and differentiate the different tissues, a catalog database is needed of all tissues including tumors.

Eligibility criteria:
inclusion criteria: * all patients with surgical procedure exclusion criteria: * inability to consent

Keywords: hyperspectral imaging tissue detection tumor detection infammatory bowel disease colorectal cancer
developing a mobile intervention to reduce suicidal cognitions in veterans

Conditions: Suicide

Summary: suicide cognitions are conceptualized as enduring, chronic vulnerability factors that predispose individuals to suicidal crises. therefore, modification of these beliefs may reduce suicidal thoughts and behaviors. the goal of this research is to develop, refine, and pilot-test a mobile intervention to reduce cognitions that contribute to elevated suicide risk and to assess the impact of reductions in suicide cognitions and anger cognitions on suicide risk and functioning.

suicide cognitions are conceptualized as enduring, chronic vulnerability factors that predispose individuals to suicidal crises. therefore, modification of these beliefs may reduce suicidal thoughts and behaviors. in addition to suicide cognitions, another potentially modifiable risk factor for suicide is anger. the goal of this research is to develop, refine, and pilot-test a mobile interpretation bias modification intervention to reduce cognitions that contribute to elevated suicide risk and to assess the impact of reductions in suicide cognitions and hostile interpretation bias (a cognitive bias that is associated with anger) on suicide risk and functioning.

Eligibility criteria:
inclusion criteria: * veterans 18 years or older * diagnosed with ptsd, established via the clinician-administered ptsd scale for dsm-5 (caps-5) * report a score of 12 on the 5-item dimensions of anger reactions scale * can read at least 6th grade level material * report a score of 1-3 (indicating ideation without intent) on the columbia-suicide severity rating scale (c-ssrs) * have attended a mental health appointment within the past month, with another scheduled in the following month (i.e., be engaged in treatment with a mental health provider) exclusion criteria: * diagnosed with bipolar or psychotic disorder. * current substance use disorder. * current imminent suicide risk or homicidal ideation requiring immediate intervention.

Keywords: suicide suicide cognitions anger mobile intervention
preoperative condition in giant obese patients

Conditions: Morbid Obesity; Bariatric Surgery Candidate

Summary: the frequency of super-super obese who need immediate weight loss surgery is risen continuously. for those patients a prior-to-surgery conditioning therapy is mandatory to gain technical and physical operability. the exclusively well-established preliminary therapy so far was the intragastric balloon, which takes 7 months of treatment time. due to life-threatening conditions of giant obese patients, who have been admitted to hospital, the investigators were forced to develop a more prompt acting conditioning therapy to bring those individuals in a short run to an improved and "fit-for-surgery" state. in such an impasse the investigators combine liraglutide with its well-known weight-loss effect with a leucine-based amino acid infusion that is generally used for patients with liver insufficiency, in expectance of an additional weight loss and liver reduction effect.

the investigators will use a commercial available amino acid infusion (aminosteril hepa 8%, fresenius karbi), which is used in clinical application for liver conditioning. it is mainly based on the branched-chained amino acid leucine (13.09 g per 1000 ml). the investigators will combine this with a daily subcutaneous injection of liraglutide. liraglutide is a glp-1 analogue, which achieved meanwhile the fda approval for weight loss treatment. initial liraglutide dosage is 1.2 mg for three days, boosted to 1.8 mg consecutively. participants receive energy reduced nutrition with 1000 kcal/d.

Eligibility criteria:
inclusion criteria: * multimorbid, super-super obese patients exclusion criteria: * renal insufficiency iii

Keywords: morbid obesity giant obese preoperative procedure liraglutide leucine
reoperation after pancreaticoduodenectomy

Conditions: Periampullary Carcinoma; Pancreatic Cancer

Summary: the aim of this study is to outline the incidence of early and late reoperation after pd, examine the risk factors for early surgical intervention and its impact on the surgical outcome, hospital stay, diseases recurrence and patient survival, address variable indications for late readmission and reoperation after pd and its impact on patient survival and disease recurrence.

this is a retrospective cohort study of all patients who underwent pd for periampullary tumors in gastrointestinal surgical center (gisc), mansoura university, egypt in the period between 2000 and 2018.the exclusion criteria included any patients with locally advanced periampullary tumor, metastases, patients with advanced liver cirrhosis (child b or c), malnutrition, or coagulopathy. patient data were recorded in a prospectively maintained database. preoperative variables included; age, sex, body mass index, patients' symptoms and signs, laboratory tests, tumor markers and preoperative biliary drainage. intraoperative variables included; liver status, tumor size, pancreatic duct diameter, texture of the pancreas, operative time, blood loss, pancreatic reconstruction method and blood transfusion. postoperative variables included postoperative complications, drain amylase, liver function, day to resume oral feeding, postoperative stay, re-exploration, hospital mortality, postoperative pathology, and surgical safety margins. data regarding reoperation included incidence, male to female ratio, hospital stay, interval to reoperation, number of explorations, indication of reoperation and surgical management, and postoperative outcome in terms of morbidity and hospital stay. follow-up was carried out one week postoperatively, 3 months, 6 months and then after one year. the minimum duration of follow up was 2 years. follow up was done by thorough history taking, clinical examination and abdominal ct in case of suspicious lesions on pelvi-abdominal ultrasound.

Eligibility criteria:
inclusion criteria: * all patients who underwent pancreaticoduodenectomy for periampullary malignant lesions in the duration between january 2000 and may 2018 exclusion criteria: * pancreaticoduodenectomy performed for benign tumors, recurrent malignant tumors, chronic pancreatitis, or inflammatory strictures were excluded from the study.

Keywords: pancreaticoduodenectomy, pancreatic fistula, pancreatic cancer, reoperation
dermatologic tacrolimus ointment on eyelids in the treatment of refractory vernal keratoconjunctivitis and atopic keratoconjunctivitis

Conditions: Vernal Keratoconjunctivitis; Atopic Keratoconjunctivitis; Tacrolimus

Summary: to evaluate the therapeutic effects of dermatologic tacrolimus ointment on eyelids to treat refractory vernal keratoconjunctivitis and atopic keratoconjunctivitis.

treatment of vernal keratoconjunctivitis (vkc) and atopic keratoconjunctivitis (akc) is a challenge for the ophthalmologist and patients because of its wide variation in presentation and recurrence in nature. patients has to be dependent on long term steroid control and suffered from complications, such as steroid glaucoma and secondary infection. about 32% of vkc patients is refractory to steroid treatment and another 35.4% of patients showed partial response. tacrolimus ointment or eye drops are promising anti-inflammatory agents that have been shown very effective against vkc for patients suffering from severe vkc resistant to topical cyclosporine. although tacrolimus eye drops is very effective in severe cases of vkc, unfortunately, it is only available in limited countries. because of the unavailability of tacrolimus eye drops and side effect of long-tern steroid use, we tried to find other options for these severe vkc and akc. because there will be concomitant atopic dermatitis in the eyelid of severe cases of vkc and akc, we retrospectively collected in cases using topical tacrolimus dermatological ointment on the skin of upper eye lid in the treatment of severe vkc and akc with concomitant atopic dermatitis. here, we reported 10 cases with either vkc or akc whose symptoms resolved significantly with dermatologic tacrolimus ointment applying on eyelids.

Eligibility criteria:
inclusion criteria: * all patients diagnosed as severe vernal keratoconjunctivitis or atopic keratoconjunctivitis and received topical dermatological tacrolimus ointment on upper eyelids between january, 2016 and january, 2018 at national taiwan university hospital. exclusion criteria: * none

Keywords: vernal keratoconjunctivitis atopic keratoconjunctivitis tacrolimus
the effects of the combined therapy of acupuncture and yoga exercise on weight loss

Conditions: Obesity

Summary: the aim of this study is to examine the effects of combination of acupuncture and ayuveda yoga exercise on weight loss for the overweight.

obesity is a common health problem in developed countries. at present,the medical staff have already been alerted that the obesity is a kind of disease actually and one of the epidemic diseases which erode the human health in the world. it is not only about the person's health but also a main public health problem. it has been caught to our attention that some diseases, such as cardiovascular diseases,diabetes, and high blood pressure are coming along with overweight and obesity. recent studies had demonstrated a positive correlation between chronic diseases and obesity. there are many treatments for the obesity, in general, acupuncture may be an effective one. acupuncture may suppress the people's appetite, slow down the stomach's creeping motion, and increase the stomach's evacuation time. simultaneously, acupuncture controls the body through the absorption and storage of the calorie via the adjustment of the endocrine system. but we still need a more efficiency way to accelerate the body fat metabolism and decrease the storage of the fat in vivo. therefore, the purpose of this study is to examine the effects of combination of acupuncture and ayuveda yoga exercise on weight loss among the overweight.

Eligibility criteria:
inclusion criteria: * bmi \> 24 exclusion criteria: * diagnosis of cancer.

Keywords: obesity, ayuveda yoga exercise, acupuncture.
congenital sucrase-isomaltase deficiency (csid) genetic prevalence study (gps)

Conditions: Congenital Sucrase-isomaltase Deficiency (CSID)

Summary: congenital sucrose-isomaltase deficiency (csid) is a rare, genetic disease in which mutations in the sucrose-isomaltase (si) gene cause digestion problems of sucrose resulting in diarrhea and abdominal pain. children with chronic, idiopathic diarrhea or abdominal pain will have their sucrose-isomaltase gene assessed for a panel of known csid mutations to determine the prevalence of these mutations in an enriched population and also determine functional deficiency using a breath test.


Eligibility criteria:
inclusion criteria: * must be 18 years of age or younger. * a primary clinical diagnosis of chronic idiopathic diarrhea or chronic abdominal pain for at least 4 weeks. * english or spanish speaking subjects and parent(s)/guardian only. * parental consent from one parent/guardian and also subject assent when appropriate based on individual irb requirements. exclusion criteria: * any condition(s) or finding(s) that in the opinion of the principal investigator suggests an alternative diagnosis for his/her gastrointestinal symptoms. * abdominal pain primarily related to constipation. * suspected gastrointestinal infectious disease. * no current use of sacrosidase (sucraid® oral solution). * known gastrointestinal disease such as celiac disease. * prior consumption of an investigational medication within the last 4 weeks. * antibiotics in the last 2 weeks, and no history of viral gastroenteritis within that same period of time. * known hepatitis b or c infection (positive hbsag or hcv within 6 months of enrollment) or subject-pugh class c liver disease of any cause, hiv infection, tuberculosis, clostridia difficile co-infection, cancer or systemic infections. * severe neurologic impairment that would prevent them from reporting a history of abdominal pain. * receiving or received biologic therapies (including infliximab, adalimumab, natalizumab) within 3 months prior to or at enrollment. * present or past use of immune modulators therapy (e.g., azathioprine, 6mp, methotrexate). * planned or previous abdominal surgery (e.g., bowel resection). * subjects with severe, uncontrolled systemic diseases. * presence of clinical alarm signs, including hypotension, anemia requiring blood transfusions, altered mental status, or inability to tolerate food and/or fluids by mouth.